Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.72 |
| ▸ | LAP3 | P28838 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 5/20 | 0.58 |
| ▸ | PPARA | Q07869 | 3/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | EPOR | P19235 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5309375 | 1.00 | LTA4H (0.72) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL2164928 | 1.00 | LTA4H (0.72) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL27546489 | 0.90 | PPARG (0.67) | LTA4HLAP3PPARGPPARAPPARD | |
| SCHEMBL27854776 | 0.88 | LTA4H (0.71) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL5375675 | 0.87 | L3MBTL1 (0.65) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL4756342 | 0.87 | L3MBTL1 (0.65) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL1596779 | 0.87 | L3MBTL1 (0.65) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL979240 | 0.86 | KMT2A (0.55) | LTA4HNPC1RAB9AMMP8 | |
| SCHEMBL180159 | 0.86 | KMT2A (0.55) | LTA4HNPC1RAB9AMMP8 | |
| SCHEMBL3980617 | 0.86 | KMT2A (0.55) | LTA4HNPC1RAB9AMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168648-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. | 2024-03-21 | — | — | US | disclosed |
| EP-4320105-A1 | OPIOID RECEPTOR MODULATORS | Epiodyne, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117425644-A | Opioid receptor modulators | 埃皮欧黛公司 | 2024-01-19 | — | — | CN | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-10 | — | — | US | disclosed |
| WO-2022216750-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20040248849-A1 | 3-Aryl-A-oxy substituted propanoic acids and a process for their preparation | DR. REDDY'S LABORATORIES INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2003008362-A1 | NOVEL 3-ARYL-2-HYDROXY PROPANOL DERIVATIVES AND A PROCESS FOR THEIR PREPARATION | DR. REDDY'S LABORATORIES LTD (IN) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003002575-A1 | 3-ARYL-$G(a)-OXY SUBSTITUTED PROPANOIC ACIDS AND A PROCESS FOR THEIR PREPARATION | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | LTA4H 2381/4885LAP3 3694/4885PPARG 395/4885 |
| US-12168648-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | LTA4H 2381/4885LAP3 3694/4885PPARG 395/4885 |
| US-11634396-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | LTA4H 2381/4885LAP3 3694/4885PPARG 395/4885 |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | LTA4H 2381/4885LAP3 3694/4885PPARG 395/4885 |
| US-20040248849-A1 | 3-Aryl-A-oxy substituted propanoic acids and a process for their preparation | GPR119, GLP1R, SLC5A1 | LTA4H 1445/4885LAP3 908/4885PPARG 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.